1. Home
  2. KNSA vs NAVI Comparison

KNSA vs NAVI Comparison

Compare KNSA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • NAVI
  • Stock Information
  • Founded
  • KNSA 2015
  • NAVI 1973
  • Country
  • KNSA United Kingdom
  • NAVI United States
  • Employees
  • KNSA N/A
  • NAVI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • NAVI Investment Bankers/Brokers/Service
  • Sector
  • KNSA Health Care
  • NAVI Finance
  • Exchange
  • KNSA Nasdaq
  • NAVI Nasdaq
  • Market Cap
  • KNSA 1.5B
  • NAVI N/A
  • IPO Year
  • KNSA 2018
  • NAVI N/A
  • Fundamental
  • Price
  • KNSA $21.37
  • NAVI $11.85
  • Analyst Decision
  • KNSA Strong Buy
  • NAVI Hold
  • Analyst Count
  • KNSA 6
  • NAVI 8
  • Target Price
  • KNSA $37.17
  • NAVI $13.25
  • AVG Volume (30 Days)
  • KNSA 663.8K
  • NAVI 724.7K
  • Earning Date
  • KNSA 04-29-2025
  • NAVI 04-30-2025
  • Dividend Yield
  • KNSA N/A
  • NAVI 5.40%
  • EPS Growth
  • KNSA N/A
  • NAVI N/A
  • EPS
  • KNSA N/A
  • NAVI 1.18
  • Revenue
  • KNSA $423,239,000.00
  • NAVI $848,000,000.00
  • Revenue This Year
  • KNSA $37.21
  • NAVI N/A
  • Revenue Next Year
  • KNSA $1.53
  • NAVI $0.14
  • P/E Ratio
  • KNSA N/A
  • NAVI $10.09
  • Revenue Growth
  • KNSA 56.60
  • NAVI N/A
  • 52 Week Low
  • KNSA $17.38
  • NAVI $10.53
  • 52 Week High
  • KNSA $28.15
  • NAVI $16.97
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 53.40
  • NAVI 47.14
  • Support Level
  • KNSA $19.62
  • NAVI $10.92
  • Resistance Level
  • KNSA $21.38
  • NAVI $12.07
  • Average True Range (ATR)
  • KNSA 1.19
  • NAVI 0.59
  • MACD
  • KNSA 0.08
  • NAVI 0.12
  • Stochastic Oscillator
  • KNSA 99.52
  • NAVI 67.12

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Share on Social Networks: